Reminder: Roche Virtual Event – Key ophthalmology data presented at the Angiogenesis 2023 Meeting
February 06, 2023 at 01:10 pm
Share
Monday 13thFebruary 2023
We are pleased to invite investors and analysts to participate in our virtual event on Monday, 13February2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February.
Roche ophthalmology strategy - Nilesh Mehta, Global Franchise Head of Ophthalmology
Roche ophthalmology pipeline - ChristopherBrittain, Vice President and Global Head of Ophthalmology Product Development
Key data presented at Angiogenesis - Veeral S.Sheth, MD, MBA, FASRS, FACS,Retina Specialist and Clinical Investigator
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event.
>click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here *.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via >ir.roche.com
Roche Holding AG published this content on 06 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 February 2023 13:09:06 UTC.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.